Skip to main content
. 2023 Oct 7;13:16950. doi: 10.1038/s41598-023-44039-0

Figure 1.

Figure 1

Selinexor (Sel) significantly increases the cytotoxic effect of bendamustine (Ben), fludarabine (F-ara-A) and idelalisib (Ide) against primary CLL cells at multiple concentrations and time points. Heatmaps show the mean viability (% of AnnV-/PI- CLL cells) for 11 samples of patients with CLL that were co-treated in vitro with selinexor + bendamustine, selinexor + fludarabine and selinexor + idelalisib at specific drug concentrations and time points. Cells highlighted with borders indicate the combinations with a CI < 1 (synergistic). Asterisks indicate the combinations which determined a significant reduction in cell viability compared to both single agents, at the corresponding concentration. ****p < 0.0001, ***p < 0.001, **p < 0.01 and *p < 0.05.